Cargando…

Debate on GMOs Health Risks after Statistical Findings in Regulatory Tests

We summarize the major points of international debate on health risk studies for the main commercialized edible GMOs. These GMOs are soy, maize and oilseed rape designed to contain new pesticide residues since they have been modified to be herbicide-tolerant (mostly to Roundup) or to produce mutated...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vendômois, Joël Spiroux, Cellier, Dominique, Vélot, Christian, Clair, Emilie, Mesnage, Robin, Séralini, Gilles-Eric
Formato: Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952409/
https://www.ncbi.nlm.nih.gov/pubmed/20941377
_version_ 1782187777620705280
author de Vendômois, Joël Spiroux
Cellier, Dominique
Vélot, Christian
Clair, Emilie
Mesnage, Robin
Séralini, Gilles-Eric
author_facet de Vendômois, Joël Spiroux
Cellier, Dominique
Vélot, Christian
Clair, Emilie
Mesnage, Robin
Séralini, Gilles-Eric
author_sort de Vendômois, Joël Spiroux
collection PubMed
description We summarize the major points of international debate on health risk studies for the main commercialized edible GMOs. These GMOs are soy, maize and oilseed rape designed to contain new pesticide residues since they have been modified to be herbicide-tolerant (mostly to Roundup) or to produce mutated Bt toxins. The debated alimentary chronic risks may come from unpredictable insertional mutagenesis effects, metabolic effects, or from the new pesticide residues. The most detailed regulatory tests on the GMOs are three-month long feeding trials of laboratory rats, which are biochemically assessed. The tests are not compulsory, and are not independently conducted. The test data and the corresponding results are kept in secret by the companies. Our previous analyses of regulatory raw data at these levels, taking the representative examples of three GM maize NK 603, MON 810, and MON 863 led us to conclude that hepatorenal toxicities were possible, and that longer testing was necessary. Our study was criticized by the company developing the GMOs in question and the regulatory bodies, mainly on the divergent biological interpretations of statistically significant biochemical and physiological effects. We present the scientific reasons for the crucially different biological interpretations and also highlight the shortcomings in the experimental protocols designed by the company. The debate implies an enormous responsibility towards public health and is essential due to nonexistent traceability or epidemiological studies in the GMO-producing countries.
format Text
id pubmed-2952409
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-29524092010-10-12 Debate on GMOs Health Risks after Statistical Findings in Regulatory Tests de Vendômois, Joël Spiroux Cellier, Dominique Vélot, Christian Clair, Emilie Mesnage, Robin Séralini, Gilles-Eric Int J Biol Sci Communication We summarize the major points of international debate on health risk studies for the main commercialized edible GMOs. These GMOs are soy, maize and oilseed rape designed to contain new pesticide residues since they have been modified to be herbicide-tolerant (mostly to Roundup) or to produce mutated Bt toxins. The debated alimentary chronic risks may come from unpredictable insertional mutagenesis effects, metabolic effects, or from the new pesticide residues. The most detailed regulatory tests on the GMOs are three-month long feeding trials of laboratory rats, which are biochemically assessed. The tests are not compulsory, and are not independently conducted. The test data and the corresponding results are kept in secret by the companies. Our previous analyses of regulatory raw data at these levels, taking the representative examples of three GM maize NK 603, MON 810, and MON 863 led us to conclude that hepatorenal toxicities were possible, and that longer testing was necessary. Our study was criticized by the company developing the GMOs in question and the regulatory bodies, mainly on the divergent biological interpretations of statistically significant biochemical and physiological effects. We present the scientific reasons for the crucially different biological interpretations and also highlight the shortcomings in the experimental protocols designed by the company. The debate implies an enormous responsibility towards public health and is essential due to nonexistent traceability or epidemiological studies in the GMO-producing countries. Ivyspring International Publisher 2010-10-05 /pmc/articles/PMC2952409/ /pubmed/20941377 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Communication
de Vendômois, Joël Spiroux
Cellier, Dominique
Vélot, Christian
Clair, Emilie
Mesnage, Robin
Séralini, Gilles-Eric
Debate on GMOs Health Risks after Statistical Findings in Regulatory Tests
title Debate on GMOs Health Risks after Statistical Findings in Regulatory Tests
title_full Debate on GMOs Health Risks after Statistical Findings in Regulatory Tests
title_fullStr Debate on GMOs Health Risks after Statistical Findings in Regulatory Tests
title_full_unstemmed Debate on GMOs Health Risks after Statistical Findings in Regulatory Tests
title_short Debate on GMOs Health Risks after Statistical Findings in Regulatory Tests
title_sort debate on gmos health risks after statistical findings in regulatory tests
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952409/
https://www.ncbi.nlm.nih.gov/pubmed/20941377
work_keys_str_mv AT devendomoisjoelspiroux debateongmoshealthrisksafterstatisticalfindingsinregulatorytests
AT cellierdominique debateongmoshealthrisksafterstatisticalfindingsinregulatorytests
AT velotchristian debateongmoshealthrisksafterstatisticalfindingsinregulatorytests
AT clairemilie debateongmoshealthrisksafterstatisticalfindingsinregulatorytests
AT mesnagerobin debateongmoshealthrisksafterstatisticalfindingsinregulatorytests
AT seralinigilleseric debateongmoshealthrisksafterstatisticalfindingsinregulatorytests